KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2023)

AbCellera Biologics' EBITDA Margin history spans 4 years, with the latest figure at 516.51% for Q4 2023.

  • For the quarter ending Q4 2023, EBITDA Margin fell 37463.0% year-over-year to 516.51%, compared with a TTM value of 385.86% through Dec 2023, down 41817.0%, and an annual FY2024 reading of 574.05%, down 18818.0% over the prior year.
  • EBITDA Margin for Q4 2023 was 516.51% at AbCellera Biologics, down from 426.9% in the prior quarter.
  • The five-year high for EBITDA Margin was 59.7% in Q2 2020, with the low at 516.51% in Q4 2023.
  • Average EBITDA Margin over 4 years is 120.79%, with a median of 22.0% recorded in 2022.
  • Year-over-year, EBITDA Margin surged 44053bps in 2022 and then tumbled -45188bps in 2023.
  • Tracing ABCL's EBITDA Margin over 4 years: stood at 56.28% in 2020, then dropped by -24bps to 42.76% in 2021, then tumbled by -432bps to 141.88% in 2022, then plummeted by -264bps to 516.51% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's EBITDA Margin are 516.51% (Q4 2023), 426.9% (Q3 2023), and 302.37% (Q2 2023).